Skip to content

Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury

EValuation Of NGAL in Early and eVolving Acute kidnEy Injury

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00445809
Acronym
EVOLVE
Enrollment
355
Registered
2007-03-09
Start date
2007-02-28
Completion date
2009-04-30
Last updated
2009-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, Acute

Keywords

Kidney, Renal, Cardiac Surgery with bypass, Cardiovascular surgery with cardiopulmonary bypass

Brief summary

Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test their plasma for a biomarker called NGAL and compare the NGAL levels to their creatinine levels. We hypothesize that NGAL is an earlier marker for kidney injury than creatinine.

Detailed description

Approximately 350 adults scheduled to undergo cardiac surgery involving the use of cardiopulmonary bypass will be enrolled. Blood samples will be obtained from all patients in the study for future measurement of both plasma NGAL and plasma creatinine levels in the same sample at each of nine time points. Blood samples for later assessment using the Triage NGAL Test will be processed to plasma at the clinical site, frozen and shipped to Biosite for storage. Testing with the Triage NGAL Test will be conducted at Biosite by trained laboratory personnel. The results of these assessments will be blinded to the medical team during the study and will not impact the medical management of the patient. The medical team caring for each study patient should obtain clinical laboratory tests per their usual post-operative routine and manage the patient accordingly. Any serum creatinine measurements obtained by the site as part of this routine care both pre-operatively and through Day 10 post-operatively will be recorded as well as any additional post-operative renal insults, the development of oliguria, the need for a nephrology consultation, initiation of dialysis and mortality will also be recorded through Day 10.

Interventions

None listed

Sponsors

Abbott RDx Cardiometabolic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

4.2.1 Inclusion Criteria 1. Male or female scheduled for cardiovascular surgery (other than cardiac transplant) requiring cardiopulmonary bypass 2. 18 years of age or older i. The first approximately 150 to200 patients enrolled must have: • A Prediction of Acute Renal Failure Score ≥ 5 (see Reference 18 and Appendix B) ii. The subsequent patients enrolled must have one or more of the following risk factors for post-bypass renal injury: * Age \> 70; * Pre-operative creatinine \> 1.4 mg/dL; * NYHA Class 3 or 4 heart failure or left ventricular ejection fraction \< 35%; * Insulin-dependent diabetes mellitus; * Undergoing cardiac valve surgery; * History of previous cardiac surgery.

Exclusion criteria

* Age \< 18 years * Inability to obtain Informed Consent from patient or representative * Prisoners or other institutionalized or vulnerable individuals * Participation in an interventional clinical study within the previous 30 days * History of previous renal transplantation * Stage 5 chronic kidney disease (estimated GRF\<15 mL/min/1.73m2) (See Appendix C) * Known or suspected ongoing pre-operative acute renal failure due to any cause, including pre-renal, intrinsic renal or post-renal (obstructive) etiologies (as evidenced by increasing serum creatinines or oliguria pre-operatively) * Already receiving dialysis, in imminent need of dialysis or considered highly likely to need dialysis in the immediate post-operative period for fluid management * Any known or suspected renal ischemic insult(such as cardiac arrest)or nephrotoxic insult(other than intravascular contrast procedure) during the 48 hours prior to surgery * Known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV)infection, hepatitis B virus (HBV) infection or other infectious hepatitis * Pre-operative hematocrit \<25%, recent blood transfusions have been administered to maintain hematocrit \>25% or any other contraindication to obtaining the study-specified blood samples * Undergoing cardiac transplantation

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026